The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein is an Effector of Tamoxifen-Induced Apoptosis

Por Naresh, Anjali, Thor, Ann D., Edgerton, Susan M., Torkko, Kathleen C., Kumar, Rakesh, Jones, Frank E.
Publicado em 2008

Tolerance of the Human Kidney to Isolated Controlled Ischemia

Por Parekh, Dipen J., Weinberg, Joel M., Ercole, Barbara, Torkko, Kathleen C., Hilton, William, Bennett, Michael, Devarajan, Prasad, Venkatachalam, Manjeri A.
Publicado em 2013

Pseudolumen Size and Perimeter in Prostate Cancer: Correlation with Patient Outcome

Por Iczkowski, Kenneth A., Torkko, Kathleen C., Kotnis, Gregory R., Wilson, R. Storey, Huang, Wei, Wheeler, Thomas M., Abeyta, Andrea M., Lucia, M. Scott
Publicado em 2011

Serum 25-hydroxyvitamin D Concentrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

Por Schenk, Jeannette M, Till, Cathee A., Tangen, Catherine M., Goodman, Phyllis J., Song, Xiaoling, Torkko, Kathleen C., Kristal, Alan R, Peters, Ulrike, Neuhouser, Marian L.
Publicado em 2014

Anterior tumors of the prostate: diagnosis and significance

Por Werahera, Priya N., Crawford, E. David, La Rosa, Francisco G., Torkko, Kathleen C., Schulte, Beth, Sullivan, Holly T., van Bokhoven, Adrie, Lucia, M. Scott, Kim, Fernando J.
Publicado no Can J Urol (2013)

Reduced Expression of GDF-15 Is Associated With Atrophic Inflammatory Lesions of the Prostate

Por Lambert, James R., Whitson, Ramon J., Iczkowski, Kenneth A., La Rosa, Francisco G., Smith, Maxwell L., Wilson, R. Storey, Smith, Elizabeth E., Torkko, Kathleen C., Gari, Hamid H., Lucia, M. Scott
Publicado no Prostate (2014)

Digital Quantification of Five High-Grade Prostate Cancer Patterns, Including the Cribriform Pattern, and Their Association With Adverse Outcome

Por Iczkowski, Kenneth A., Torkko, Kathleen C., Kotnis, Gregory R., Wilson, R. Storey, Huang, Wei, Wheeler, Thomas M., Abeyta, Andrea M., La Rosa, Francisco G., Cook, Shelly, Werahera, Priya N., Lucia, M. Scott
Publicado no Am J Clin Pathol (2011)

Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers

Por Gari, Hamid H., Gearheart, Christy M., Fosmire, Susan, DeGala, Gregory D., Fan, Zeying, Torkko, Kathleen C., Edgerton, Susan M., Lucia, M. Scott, Ray, Rahul, Thor, Ann D., Porter, Christopher C., Lambert, James R.
Publicado no Oncotarget (2016)

Cooperative Dynamics of AR and ER Activity in Breast Cancer

Por D’Amato, Nicholas C., Gordon, Michael A., Babbs, Beatrice L., Spoelstra, Nicole S., Carson Butterfield, Kiel T., Torkko, Kathleen C., Phan, Vernon T., Barton, Valerie N., Rogers, Thomas J., Sartorius, Carol A, Elias, Anthony D., Gertz, Jason, Jacobsen, Britta M., Richer, Jennifer K.
Publicado no Mol Cancer Res (2016)

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

Por Cochrane, Dawn R, Bernales, Sebastián, Jacobsen, Britta M, Cittelly, Diana M, Howe, Erin N, D’Amato, Nicholas C, Spoelstra, Nicole S, Edgerton, Susan M, Jean, Annie, Guerrero, Javier, Gómez, Francisco, Medicherla, Satyanarayana, Alfaro, Iván E, McCullagh, Emma, Jedlicka, Paul, Torkko, Kathleen C, Thor, Ann D, Elias, Anthony D, Protter, Andrew A, Richer, Jennifer K
Publicado em 2014